This was the stock's third consecutive day of losses.

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time.

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

AbbVie的股价在过去12个月上涨了约11.8%。FactSet数据显示，超过60%的分析师对该股给予买入或增持评级，其平均目标价为179.44美元，意味着有13.7%的上涨潜力。 分析师对该股看法有分歧，仅有39%的人给予买入或增持评级。根据FactSet的数据，其平均目标价为14.83美元，意味着有11.9%的上涨潜力。

As September came to a close, health care stocks had returned about 12% in 2024. But from that point through mid-December, S&P 500 health care stocks plummeted in value as investo ...